In conclusion, the study demonstrated that EA at BL23 exhibited anti‐HUA and nephroprotective effects by inhibiting both the NLRP3 inflammasome and the IL‐6/JAK/STAT3 signaling pathway, reducing renal inflammation and supporting its therapeutic potential for HUA‐associated kidney injury. Here, NLRP3 is linked to kidney injury.